Acute Myeloid Leukemia

The Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT) observed that venetoclax combined with 5 + 2 induction chemotherapy was safe and tolerable in older patients with AML who were fit.³¹

The randomized, doubleblind, placebo-controlled phase III QUAZAR AML001 trial showed that oral azacitidine maintenance improves survival in transplant-ineligible AML.³²

Around 64% of the patients with intensive chemo-ineligible AML treated with magrolimab plus azacitidine achieved an objective response and 56% of patients achieved a complete response (unpublished data).

The VIALE-A trial observed that in previously untreated patients ineligible for intensive chemotherapy, OS was longer, and remission was higher in those who received azacitidine and venetoclax compared to azacitidine alone.³³